5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 30.31▲ | 30.21▲ | 30.27▲ | 30.35▲ | 31.02▼ |
MA10 | 30.16▲ | 30.31▲ | 30.40▲ | 30.81▼ | 29.95▲ |
MA20 | 30.16▲ | 30.43▲ | 30.30▲ | 30.85▼ | 28.78▲ |
MA50 | 30.35▲ | 30.37▲ | 30.65▼ | 28.87▲ | 28.53▲ |
MA100 | 30.28▲ | 30.76▼ | 31.12▼ | 28.48▲ | N/A |
MA200 | 30.35▲ | 31.11▼ | 30.57▼ | 29.92▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.058▲ | -0.017▼ | 0.021▲ | -0.234▼ | 0.244▲ |
RSI | 59.863▲ | 53.117▲ | 51.115▲ | 51.213▲ | 53.380▲ |
STOCH | 65.432 | 20.273 | 40.358 | 30.404 | 77.595 |
WILL %R | -7.407▲ | -54.545 | -44.776 | -61.598 | -25.561 |
CCI | 176.615▲ | 23.933 | 6.075 | -60.903 | 56.924 |
Wednesday, February 24, 2021 02:48 PM
"The initiation of our Phase 2b HARMONY study is an important milestone that builds on strong data from our Phase 2a BALANCED study," said Andrew Cheng, M.D., Ph.D., President and CEO of Akero ...
|
Wednesday, February 24, 2021 05:44 AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced it has screened the ...
|
Wednesday, February 24, 2021 12:18 AM
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/03/21 | 30.81 | 31.10 | 30.00 | 30.50 | 128,157 |
26/02/21 | 30.53 | 31.13 | 29.82 | 30.40 | 199,268 |
25/02/21 | 30.92 | 31.0811 | 29.76 | 29.82 | 210,056 |
24/02/21 | 30.25 | 30.92 | 29.8799 | 30.75 | 144,483 |
23/02/21 | 30.00 | 31.13 | 29.01 | 30.27 | 216,251 |
22/02/21 | 31.625 | 31.9405 | 30.18 | 30.34 | 204,612 |
19/02/21 | 31.45 | 32.09 | 31.09 | 31.58 | 150,902 |
18/02/21 | 32.39 | 32.80 | 31.17 | 31.35 | 151,680 |
17/02/21 | 30.95 | 32.67 | 30.23 | 32.41 | 166,236 |
16/02/21 | 30.40 | 31.15 | 30.27 | 30.71 | 117,856 |
|
|
||||
|
|
||||
|
|